The new cluster will assist regulators in harmonizing their efforts to keep medicines safe, according to FDA.

FDA and EU Agency Launch Medicine Safety Cluster

The two agencies are holding monthly teleconferences about pharmacovigilance issues, and Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency are participating as observers.

The U.S. Food and Drug Administration announced Feb. 19 that is has expanded its collaboration with the European Medicines Agency by setting up a cluster on medicine safety (pharmacovigilance) topics, including biosimilars -- biological products that are highly similar to already approved biological products; the Affordable Care Act established an abbreviated approval pathway for them -- along with medicines to treat cancer, orphan medicines, medicines for children, and blood-based products. The two agencies are holding monthly teleconferences about these and other issues.

Clusters are regular meetings between EMA, which is a European Union agency based in London, and regulators outside the European Union. They focus on specific topic areas that have been identified as requiring an intensified exchange of information and collaboration, according to FDA's announcement. "Building on the experience of previous regular videoconferences between the FDA and the EMA in this area and on the recent creation of the EMA's Pharmacovigilance Risk Assessment Committee, this cluster will provide a forum for a more systematic and focused exchange of information on the safety of medicines," it states.

Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency are participating in the pharmacovigilance cluster as observers. "The work of protecting the health and safety of the American people cannot be done in isolation," said Dr. Janet Woodcock, director of FDA's Center for Drug Evaluation and Research. "It is part of a larger collaborative global effort between the FDA and its international regulatory partners to ensure the health and safety of all our citizens."

The new cluster will assist regulators in harmonizing their efforts to keep medicines safe, according to FDA, which noted that the information exchange "is covered by confidentiality arrangements between the FDA and the other participants."

Download Center

  • Lone Worker Safety Guide

    As organizations digitalize and remote operations become more commonplace, the number of lone workers is on the rise. These employees are at increased risk for unaddressed workplace accidents or emergencies. This guide was created to help employers better understand common lone worker risks and solutions for lone worker risk mitigation and incident prevention.

  • Online Safety Training Buyer's Guide

    Use this handy buyer's guide to learn the basics of selecting online safety training and how to use it at your workplace.

  • COVID Return-to-Work Checklist, Fall 2021

    Use this checklist as an aid to help your organization return to work during the COVID-19 pandemic in a safe and healthy manner.

  • SDS Buyer's Guide

    Learn to make informed decisions while searching for SDS Management Software.

  • Risk Matrix Guide

    Risk matrices come in many different shapes and sizes. Understanding the components of a risk matrix will allow you and your organization to manage risk effectively.

  • Industry Safe

Featured Whitepapers

OH&S Digital Edition

  • OHS Magazine Digital Edition - November December 2021

    November December 2021

    Featuring:

    • GAS DETECTION
      How to Streamline Gas Detector Maintenance
    • OSHA TOP 10
      OSHA's Top 10 Most Frequently Cited Standards for FY 2021
    • PROTECTIVE APPAREL
      How PPE Can Help You Deal with the Harsh Condition of Winter
    • HEARING PROTECTION
      Tackling Hearing Protection in the Workplace
    View This Issue